- Report
- November 2021
- 365 Pages
Global
From €3203EUR$3,500USD£2,783GBP
- Report
- August 2022
- 329 Pages
Global
From €3377EUR$3,690USD£2,934GBP
- Report
- July 2022
- 180 Pages
Global
From €3377EUR$3,690USD£2,934GBP
- Book
- April 2018
- 200 Pages
- Book
- August 2022
- 656 Pages
- Book
- February 2022
- 288 Pages
- Book
- March 2021
- 288 Pages
Spain
- Book
- September 2020
- 528 Pages
- Book
- April 2018
- 384 Pages
- Book
- February 2015
- 480 Pages
- Book
- October 2014
- 296 Pages
- Book
- April 2013
- 720 Pages
- Book
- November 2012
- 656 Pages
- Book
- June 2012
- 144 Pages
- Book
- December 2010
- 528 Pages
Global
- Book
- April 2010
- 322 Pages
- Book
- May 2024
- 224 Pages
- Book
- September 2023
- 272 Pages
- Book
- September 2023
- 272 Pages

The Epidemic market within the context of Biotechnology is a sector of the industry that focuses on the development of products and services to address the challenges posed by the spread of infectious diseases. This includes the development of vaccines, diagnostics, treatments, and other preventive measures. It also includes the development of technologies to monitor and track the spread of disease, as well as the development of public health policies and strategies to reduce the impact of epidemics.
The Epidemic market is a rapidly growing sector of the biotechnology industry, with many companies investing in research and development to create new products and services. Companies in this market include Gilead Sciences, Moderna, Johnson & Johnson, Novavax, Inovio Pharmaceuticals, and Regeneron Pharmaceuticals. Show Less Read more